Stock Information
TG Therapeutics Inc (TGTX)
Ticker Symbol: TGTX
Exchange: NASDAQ
Sector: Biotechnology
Market Cap: $5,323.20 mil
Piotroski score: 6
PE Ratio: 12.4021
EPS (TTM): 2.777
Revenue (TTM): $3.87 M
Dividend Yield: N/A%
ROE: 101.12%
Latest News
-
TG Therapeutics Completes Enrollment In A Phase 3 Trial Evaluating Subcutaneous BRIUMVI, Its Anti-CD20 Monoclonal Antibody, In People With Relapsing Forms Of Multiple Sclerosis
Wed, Apr 15, 2026 7:48 AM
-
TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI
Wed, Apr 15, 2026 7:31 AM
Key Financials
Financial data not available
